Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.39 |
| ▸ | CES2 | O00748 | 2/20 | 0.36 |
| ▸ | CES1 | P23141 | 2/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | ALB | P02768 | 1/20 | 0.30 |
| ▸ | ERN1 | O75460 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5636759 | 0.83 | TAAR1 (0.41) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL5702104 | 0.82 | ACHE (0.39) | ACHECES2CES1BCHENFE2L2 | |
| SCHEMBL5701891 | 0.71 | RAPGEF4 (0.33) | CES2CES1ALDH1A1ERN1 | |
| SCHEMBL5951408 | 0.70 | CES2 (0.38) | ACHECES2CES1BCHEKDM4E | |
| SCHEMBL5702143 | 0.69 | SMN1; SMN2 (0.36) | ACHEKDM4ESMN1; SMN2 | |
| SCHEMBL5951303 | 0.69 | ACHE (0.43) | ACHECES2CES1NFE2L2ALDH1A1 | |
| SCHEMBL5637066 | 0.67 | TSHR (0.35) | — | |
| SCHEMBL2653065 | 0.65 | — | — | |
| SCHEMBL5638102 | 0.65 | KIF11 (0.39) | CES1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL254224 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE39679-E1 | Substituted heterocycle fused gamma-carbolines | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-06-05 | — | — | US | disclosed |
| EP-1211256-B1 | Method for purifying fluoroaryl metal compound | NIPPON CATALYTIC CHEM IND (JP) | 2006-08-02 | — | — | EP | disclosed |
| US-6713471-B1 | SUCH AS TERT-BUTYL-1-METHYL-6,7,9,12-TETRAHYDRO-5H-PYRIDO-(4,3-B)(1,4) THIAZEPINO(2,3,4-HI)INDOLE-11(10H)-CARBOXYLATE; SEROTONIN AGONISTS AND ANTAGONISTS; CENTRAL NERVOUS SYSTEM DISORDERS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-03-30 | — | — | US | disclosed |
| US-6509488-B2 | Magnesium halide is precipitated and removed from solution containing fluoroaryl metal compound, magnesium halide, and ether solvent, or magnesium halide is removed by treating solution with acid | NIPPON SHOKUBAI CO., LTD. (JP) | 2003-01-21 | — | — | US | disclosed |
| EP-1211256-A2 | Method for purifying fluoroaryl metal compound | Nippon Shokubai Co., Ltd. (JP) | 2002-06-05 | — | — | EP | disclosed |
| US-20020065425-A1 | Method for purifying fluoroaryl metal compound | NIPPON SHOKUBAI CO., LTD. (JP) | 2002-05-30 | — | — | US | disclosed |
| EP-1192165-A2 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES | Bristol-Myers Squibb Pharma Company (US) | 2002-04-03 | — | — | EP | disclosed |
| WO-2000077010-A2 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065425-A1 | Method for purifying fluoroaryl metal compound | MLLT3, AFF2, AFF4 | ACHE 42/4885CES2 2108/4885CES1 2877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.